Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ciliary microtubule-associated protein 3 (CIMAP3) is a cytoskeletal protein that participates in the process of primary cilia disassembly. It is specifically required for controlling cilia retraction and for the liberation and duplication of the basal body/centrosome, likely by stimulating AURKA (Aurora kinase A) activity at the basal body in a cell cycle-dependent manner. CIMAP3 is predicted to localize to the ciliary basal body and the trans-Golgi network, and has protein binding and enzyme binding activities. Genetic mutations in CIMAP3 are linked to human ciliopathies and disordered developmental syndromes characterized by defects in cilia-mediated signaling and structure[1][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ciliary microtubule-associated protein 3 (CIMAP3).